Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
Globe Newswire•06/10/2026•09:20 ET
0
Key Highlights
- ➤Kevin Lundquist appointed CFO as Outlook Therapeutics transitions to commercial-stage company
- ➤FDA approved LYTENAVA as the only U.S.-approved ophthalmic bevacizumab for wet AMD
- ➤Outlook Therapeutics advances toward LYTENAVA’s U.S. commercial launch
- ➤LYTENAVA commercial launch commenced in Germany, Austria, and the UK
- ➤LYTENAVA holds European Commission and UK marketing authorizations for wet AMD
Expert Statements
Kevin Lundquist, Chief Financial Officer of Outlook Therapeutics
“Joining Outlook Therapeutics at this point in the Company’s evolution was a compelling opportunity. With FDA approval of LYTENAVA, we have entered an important new chapter as we transition into a commercial-stage company. I look forward to helping execute on our strategy, supporting the successful launch of LYTENAVA, and working to build long-term value for shareholders.”
Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company’s path forward following the FDA approval of LYTENAVA™
ISELIN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it participated in a Virtual Investor "What This Means" segment featuring Kevin Lundquist, the Company’s recently appointed Chief Financial Officer
Get started
Create a free account to read the full story.